Anchen Pharmaceuticals, Inc. Sustainability Profile
Anchen Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2002, the company has established itself as a leader in the development and commercialisation of generic and specialty pharmaceuticals, focusing primarily on the therapeutic areas of pain management and central nervous system disorders. With a commitment to quality and innovation, Anchen Pharmaceuticals offers a range of unique products that cater to the evolving needs of healthcare providers and patients. The company has achieved significant milestones, including the successful launch of several high-demand generic medications, solidifying its market position. Anchen's dedication to excellence and patient care continues to drive its growth and reputation within the pharmaceutical landscape.
DitchCarbon Score
How does Anchen Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Anchen Pharmaceuticals, Inc.'s score of 33 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Anchen Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Endo Inc., which means that any emissions data or climate commitments may be inherited from its parent organisation. However, no specific reduction targets or climate pledges have been documented for Anchen Pharmaceuticals. As a subsidiary, Anchen Pharmaceuticals may align with the broader sustainability initiatives of Endo Inc., which could include commitments to reduce emissions and improve environmental performance. Unfortunately, without specific data or targets from Anchen Pharmaceuticals itself, it is challenging to provide a detailed overview of their carbon emissions or climate commitments. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction strategies, often setting science-based targets to mitigate their environmental impact. Anchen Pharmaceuticals may be expected to follow suit, but specific initiatives or targets have not been disclosed at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 27,475,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 37,395,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
How Carbon Intensive is Anchen Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Anchen Pharmaceuticals, Inc.'s Location?
Anchen Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Anchen Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
